GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InspireMD Inc (FRA:II2) » Definitions » Cyclically Adjusted Price-to-FCF

InspireMD (FRA:II2) Cyclically Adjusted Price-to-FCF : (As of May. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is InspireMD Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


InspireMD Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for InspireMD's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InspireMD Cyclically Adjusted Price-to-FCF Chart

InspireMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

InspireMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InspireMD's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, InspireMD's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InspireMD's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where InspireMD's Cyclically Adjusted Price-to-FCF falls into.



InspireMD Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

InspireMD's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, InspireMD's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.12/129.4194*129.4194
=-0.120

Current CPI (Dec. 2023) = 129.4194.

InspireMD Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 -5,480.769 103.349 -6,863.319
201709 -6,235.714 104.136 -7,749.726
201712 -759.000 104.011 -944.412
201803 -481.667 105.290 -592.054
201806 -211.222 106.317 -257.120
201809 -29.056 106.507 -35.307
201812 -31.725 105.998 -38.735
201903 -56.107 107.251 -67.704
201906 -28.826 108.070 -34.521
201909 -15.900 108.329 -18.995
201912 -5.590 108.420 -6.673
202003 -6.916 108.902 -8.219
202006 -1.559 108.767 -1.855
202009 -1.111 109.815 -1.309
202012 -0.551 109.897 -0.649
202103 -0.503 111.754 -0.583
202106 -0.278 114.631 -0.314
202109 -0.472 115.734 -0.528
202112 -0.341 117.630 -0.375
202203 -0.485 121.301 -0.517
202206 -0.391 125.017 -0.405
202209 -0.687 125.227 -0.710
202212 -0.387 125.222 -0.400
202303 -0.560 127.348 -0.569
202306 -0.148 128.729 -0.149
202309 -0.114 129.860 -0.114
202312 -0.120 129.419 -0.120

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


InspireMD  (FRA:II2) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


InspireMD Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of InspireMD's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


InspireMD (FRA:II2) Business Description

Traded in Other Exchanges
Address
4 Menorat Hamaor Street, Tel Aviv, ISR, 6744832
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.

InspireMD (FRA:II2) Headlines

No Headlines